Fig. 3: CDH17 x GUCY2C BsADCs demonstrate potent anti-tumor efficacy in vitro. | Cell Death Discovery

Fig. 3: CDH17 x GUCY2C BsADCs demonstrate potent anti-tumor efficacy in vitro.

From: Development of a bispecific CDH17-GUCY2C ADC bearing the ferroptosis inducer RSL3 for the treatment of colorectal cancer

Fig. 3

A The chemical structure of CDH17 x GUCY2C BsADC, composed of BsAb, an Ala-Val linker, and the ferroptosis inducer payload RSL3-NH2. The linker and payload were conjugated to BsAb with an average drug/antibody ratio of 4. B The conjugated drug distribution by the reverse phase chromatographic analysis. C In vitro cytotoxicity of CDH17 x GUCY2C BsADCs and control ADC against SW1463 and LS1034 cells. The cancer cells were treated with ADC molecules for 72 h, and cell viability was measured with a CCK-8 kit. Bystander killing assay. Cytotoxicity induced on CDH17/GUCY2C positive cells (SW1463, LS1034), CDH17/GUCY2C negative cells HT-29 and SW1463/HT-29 or LS1034/HT-29 co-cultures with 5 µg/mL of CDH17 x GUCY2C BsADC (D) or IgG1-ADC (E). *, p < 0.05; **, p < 0.01.

Back to article page